Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:06 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4RecruitingINTERVENTIONAL

Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients

ClinicalTrials.gov · NCT06881628 · Registry updated: 2025-03-18

Condition / research focus: Upper Gastrointestinal Bleeding (UGIB); Variceal Bleeding; Cirrhosis
Sponsor: Tanta University
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-12-02. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tranexamic Acid and vitamin K (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Tanta University Hospitals
Tanta, Gharbyea, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

ClinicalTrials.gov · NCT03792555 · Registry updated: 2025-03-17

Condition / research focus: Acromegaly
Sponsor: Crinetics Pharmaceuticals Inc.
Countries with listed sites: Brazil · Greece · Hungary · New Zealand · Poland · Serbia · Slovakia · United States
Registry dates and results: Start: 2019-03-11. Completion: 2020-08-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Paltusotine (drug) — also listed as: CRN00808
Placebo (drug)

Where the study takes place — 11 listed sites

Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
The Research Institute of Dallas
Dallas, Texas, United States
Site recruitment: Not reported
CETI - Centro de Estudos em Terapias Inovadoras
Curitiba, Brazil
Site recruitment: Not reported
CPQuali Pesquisa Clinica
São Paulo, Brazil
Site recruitment: Not reported
General Hospital of Athens "Gennimatas"
Athens, Greece
Site recruitment: Not reported
Semmelweis University Faculty of Medicine
Budapest, Hungary
Site recruitment: Not reported
University of Pécs Medical School
Pécs, Hungary
Site recruitment: Not reported
Endocrine, Diabetes and Research Centre, Wellington Hospital
Wellington, New Zealand
Site recruitment: Not reported
The Centre of Postgraduate Medical Education
Warsaw, Poland
Site recruitment: Not reported
Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Belgrade, Serbia
Site recruitment: Not reported
National Institute of Endocrinology and Diabetology
Ľubochňa, Slovakia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

ClinicalTrials.gov · NCT02457156 · Registry updated: 2025-03-13

Condition / research focus: Pancreatic Cancer
Sponsor: University of Liverpool
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2015-04-23. Completion: 2019-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blumgart Anastomosis (procedure) — also listed as: Pancreatico-jejunostomy
Cattell-Warren Anastomosis (procedure) — also listed as: Pancreatico-jejunostomy
Octreotide (drug) — also listed as: Sandostatin

Where the study takes place — 1 listed sites

Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide

ClinicalTrials.gov · NCT00463983 · Registry updated: 2025-03-05

Condition / research focus: Idiopathic Pulmonary Fibrosis
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Countries with listed sites: France
Registry dates and results: Start: 2006-10. Completion: 2012-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

octreotide (drug)

Where the study takes place — 16 listed sites

Service de Pneumologie Hôpital Avicenne 125 rue de Stalingrad
Bobigny, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Ambroise Paré
Boulogne-Billancourt, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Côte de Nacre
Caen, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Antoine Béclère
Clamart, France
Site recruitment: Not reported
Service de Pneumologie Centre hospitalier intercommunal de Créteil
Créteil, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Albert calmette
Lille, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Sainte Marguerite BP 29
Marseille, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Saint-Antoine
Paris, France
Site recruitment: Not reported
Hôpital Bichat 46 rue Henri Huchard
Paris, France
Site recruitment: Not reported
Service de Pneumologie A Hôpital Bichat 1
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Saint Louis 1 avenue Claude-Vellefaux
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital de la Pitié-Salpetrière 47-83 boulevard de l'hôpital
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Cochin
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Georges Pompidou
Paris, France
Site recruitment: Not reported
Service de Pneumologie A Hôpital Tenon
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

ClinicalTrials.gov · NCT02795858 · Registry updated: 2025-02-19

Condition / research focus: Carcinoid Tumors
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2016-06-14. Completion: 2023-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ramucirumab (drug) — also listed as: Cyramza
Somatostatin Analog (drug) — also listed as: octreotide, lanreotide

Where the study takes place — 2 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

ClinicalTrials.gov · NCT02691078 · Registry updated: 2025-02-04

Condition / research focus: Neuroendocrine Tumors
Sponsor: Latin American Cooperative Oncology Group
Countries with listed sites: Brazil
Registry dates and results: Start: 2016-07. Completion: 2018-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide (other)

Where the study takes place — 1 listed sites

Instituto do Cérebro do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

ClinicalTrials.gov · NCT02736448 · Registry updated: 2025-01-13

Condition / research focus: Gastro-entero-pancreatic Neuroendocrine Tumors
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2016-05. Completion: 2023-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Capecitabine (drug)
Lu-PRRT (drug)
SS-LAR (drug)

Where the study takes place — 1 listed sites

Irst Irccs
Meldola, FC, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Polydeoxyribonucleotide for Elbow Lateral Epicondylitis

ClinicalTrials.gov · NCT06753630 · Registry updated: 2024-12-31

Condition / research focus: Lateral Epicondylitis; Extracorporeal Shockwave Therapy; Muscle Strengthening
Sponsor: Chuncheon Sacred Heart Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2014-11-20. Completion: 2016-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Extensor Muscle Strengthening Exercise (behavioral)
Extracorporeal Shockwave Therapy (procedure)
Saline injection (Octreotide LAR placebo) (drug)
Polydeoxyribonucleotide Injection (drug)

Where the study takes place — 1 listed sites

Chuncheon Sacred Heart Hospital
Chuncheon, Gangwon-do, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

ClinicalTrials.gov · NCT04917484 · Registry updated: 2024-12-09

Condition / research focus: Neuroendocrine Neoplasm
Sponsor: Tine Gregersen, MD
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-02-01. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lu-177-DOTA-Octreotide (drug)

Where the study takes place — 1 listed sites

Aarhus University Hospital, department of Nuclear medicine and PET centre
Aarhus, Palle Juul-Jensens Boulevard, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

ClinicalTrials.gov · NCT05833217 · Registry updated: 2024-12-04

Condition / research focus: Long COVID; Insulin Resistance; Insulin Sensitivity
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-06. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Adipose Tissue Biopsy (procedure)
Steady State Plasma Glucose (SSPG) Test (diagnostic_test) — also listed as: Insulin Sensitivity Test

Where the study takes place — 2 listed sites

Clinical and Translational Research Unit
Palo Alto, California, United States
Site recruitment: Enrolling by invitation
Stanford Health
Palo Alto, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

ClinicalTrials.gov · NCT04871204 · Registry updated: 2024-10-31

Condition / research focus: Esophageal Cancer; Gastric Cancer
Sponsor: Fredrik Klevebro
Countries with listed sites: Sweden
Registry dates and results: Start: 2021-06-16. Completion: 2024-02-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide Injection (drug)

Where the study takes place — 1 listed sites

Karolinska University Hospital, Huddinge
Stockholm, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

ClinicalTrials.gov · NCT06505395 · Registry updated: 2024-08-26

Condition / research focus: Gastrointestinal Neuroendocrine Pancreatic Tumor
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-30. Completion: 2028-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SYHX2008 injection (drug)
Sandostatin LAR@ (drug)

Where the study takes place — 1 listed sites

Chinese PLA General Hosptial
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

ClinicalTrials.gov · NCT06045260 · Registry updated: 2024-08-13

Condition / research focus: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2023-09-13. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

177Lu-DOTATOC (drug)

Where the study takes place — 2 listed sites

AUSL Romagna - Ospedale "M. Bufalini"
Cesena, Forlì-Cesena, Italy
Site recruitment: Not yet recruiting
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Meldola, Forlì-Cesena, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Sandostatin LAR® in Acromegaly

ClinicalTrials.gov · NCT01424241 · Registry updated: 2024-07-24

Condition / research focus: Acromegaly
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2006-10. Completion: 2014-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sandostatin LAR (drug)

Where the study takes place — 1 listed sites

Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

Dexamethasone/Pancreatic Clamp P&F

ClinicalTrials.gov · NCT06126354 · Registry updated: 2024-07-10

Condition / research focus: Insulin Resistance; Prediabetic State; Non-Alcoholic Fatty Liver Disease; Overweight and Obesity
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-01. Completion: 2026-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (12)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin human (drug) — also listed as: Novolin-R, Humulin-R
Octreotide Acetate (drug) — also listed as: Octreotide Acetate IV
Glucagon (drug) — also listed as: Glucagon IV
Human Growth Hormone (drug) — also listed as: Omnitrope
Dexamethasone Oral (drug) — also listed as: Dexamethasone
[6,6-2H2] D-glucose (other) — also listed as: D2-glucose, D2G
20% D-glucose (aq) (drug) — also listed as: D20W
BOOST Plus (dietary_supplement)
Harvard Apparatus PHD ULTRA CP syringe pump (device)
Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer (device)
Normal saline (other) — also listed as: NaCl IV
Human albumin (other) — also listed as: Human albumin IV

Where the study takes place — 1 listed sites

Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

ClinicalTrials.gov · NCT05701241 · Registry updated: 2024-06-14

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: University Hospital, Antwerp
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2023-06-28. Completion: 2034-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatostatin analog (drug) — also listed as: lanreotide, octreotide, sandostatin, somatuline

Where the study takes place — 19 listed sites

AZ Klina
Brasschaat, Antwerp, Belgium
Site recruitment: Recruiting
AZ Rivierenland
Rumst, Antwerp, Belgium
Site recruitment: Active, not recruiting
Ghent University Hospital
Ghent, East Flanders, Belgium
Site recruitment: Active, not recruiting
VITAZ
Sint-Niklaas, East-Flanders, Belgium
Site recruitment: Recruiting
University Hospital Leuven
Leuven, Flemish Brabant, Belgium
Site recruitment: Recruiting
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Site recruitment: Active, not recruiting
AZ Monica
Antwerp, Belgium
Site recruitment: Not yet recruiting
GZA
Antwerp, Belgium
Site recruitment: Active, not recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium
Site recruitment: Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Site recruitment: Recruiting
H.U.B.
Brussels, Belgium
Site recruitment: Active, not recruiting
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Recruiting
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Active, not recruiting
Rijnstate
Arnhem, Gelderland, Netherlands
Site recruitment: Recruiting
Maastricht UMC+
Maastricht, Limburg, Netherlands
Site recruitment: Recruiting
Maxima Medisch Centrum
Eindhoven, North Brabant, Netherlands
Site recruitment: Active, not recruiting
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Site recruitment: Active, not recruiting
UMC Groningen
Groningen, Netherlands
Site recruitment: Recruiting
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

ClinicalTrials.gov · NCT05359146 · Registry updated: 2024-04-19

Condition / research focus: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Sponsor: University Hospital, Basel, Switzerland
Countries with listed sites: Switzerland
Registry dates and results: Start: 2023-03-28. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

161Tb-DOTA-LM3 (drug)
177Lu-DOTATOC (drug)

Where the study takes place — 1 listed sites

Division of Nuclear Medicine, University Hospital Basel
Basel, Switzerland
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

ClinicalTrials.gov · NCT01070758 · Registry updated: 2024-04-18

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatuline autogel

Where the study takes place — 1 listed sites

Pediatric Endocrinology Unit, Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Resection of the Esophagus and Subsequent Weight Loss

ClinicalTrials.gov · NCT03377660 · Registry updated: 2024-03-27

Condition / research focus: Esophageal Cancer; Weight Gain; Eating Behavior; Food Reward
Sponsor: Imperial College London
Countries with listed sites: Ireland
Registry dates and results: Start: 2018-01-01. Completion: 2023-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clinical treatment (other)

Where the study takes place — 1 listed sites

Conway Institute, UCD
Dublin, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

ClinicalTrials.gov · NCT06300216 · Registry updated: 2024-03-08

Condition / research focus: Neuroendocrine Tumors
Sponsor: Qilu Hospital of Shandong University
Countries with listed sites: China
Registry dates and results: Start: 2024-03-26. Completion: 2028-05-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide microspheres (drug)

Where the study takes place — 1 listed sites

Qilu hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:06 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4RecruitingINTERVENTIONAL

Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients

ClinicalTrials.gov · NCT06881628 · Registry updated: 2025-03-18

Condition / research focus: Upper Gastrointestinal Bleeding (UGIB); Variceal Bleeding; Cirrhosis
Sponsor: Tanta University
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-12-02. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tranexamic Acid and vitamin K (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Tanta University Hospitals
Tanta, Gharbyea, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

ClinicalTrials.gov · NCT03792555 · Registry updated: 2025-03-17

Condition / research focus: Acromegaly
Sponsor: Crinetics Pharmaceuticals Inc.
Countries with listed sites: Brazil · Greece · Hungary · New Zealand · Poland · Serbia · Slovakia · United States
Registry dates and results: Start: 2019-03-11. Completion: 2020-08-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Paltusotine (drug) — also listed as: CRN00808
Placebo (drug)

Where the study takes place — 11 listed sites

Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
The Research Institute of Dallas
Dallas, Texas, United States
Site recruitment: Not reported
CETI - Centro de Estudos em Terapias Inovadoras
Curitiba, Brazil
Site recruitment: Not reported
CPQuali Pesquisa Clinica
São Paulo, Brazil
Site recruitment: Not reported
General Hospital of Athens "Gennimatas"
Athens, Greece
Site recruitment: Not reported
Semmelweis University Faculty of Medicine
Budapest, Hungary
Site recruitment: Not reported
University of Pécs Medical School
Pécs, Hungary
Site recruitment: Not reported
Endocrine, Diabetes and Research Centre, Wellington Hospital
Wellington, New Zealand
Site recruitment: Not reported
The Centre of Postgraduate Medical Education
Warsaw, Poland
Site recruitment: Not reported
Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
Belgrade, Serbia
Site recruitment: Not reported
National Institute of Endocrinology and Diabetology
Ľubochňa, Slovakia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

ClinicalTrials.gov · NCT02457156 · Registry updated: 2025-03-13

Condition / research focus: Pancreatic Cancer
Sponsor: University of Liverpool
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2015-04-23. Completion: 2019-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blumgart Anastomosis (procedure) — also listed as: Pancreatico-jejunostomy
Cattell-Warren Anastomosis (procedure) — also listed as: Pancreatico-jejunostomy
Octreotide (drug) — also listed as: Sandostatin

Where the study takes place — 1 listed sites

Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide

ClinicalTrials.gov · NCT00463983 · Registry updated: 2025-03-05

Condition / research focus: Idiopathic Pulmonary Fibrosis
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Countries with listed sites: France
Registry dates and results: Start: 2006-10. Completion: 2012-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

octreotide (drug)

Where the study takes place — 16 listed sites

Service de Pneumologie Hôpital Avicenne 125 rue de Stalingrad
Bobigny, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Ambroise Paré
Boulogne-Billancourt, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Côte de Nacre
Caen, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Antoine Béclère
Clamart, France
Site recruitment: Not reported
Service de Pneumologie Centre hospitalier intercommunal de Créteil
Créteil, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Albert calmette
Lille, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Sainte Marguerite BP 29
Marseille, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Saint-Antoine
Paris, France
Site recruitment: Not reported
Hôpital Bichat 46 rue Henri Huchard
Paris, France
Site recruitment: Not reported
Service de Pneumologie A Hôpital Bichat 1
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Saint Louis 1 avenue Claude-Vellefaux
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital de la Pitié-Salpetrière 47-83 boulevard de l'hôpital
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Cochin
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Georges Pompidou
Paris, France
Site recruitment: Not reported
Service de Pneumologie A Hôpital Tenon
Paris, France
Site recruitment: Not reported
Service de Pneumologie Hôpital Pontchaillou
Rennes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

ClinicalTrials.gov · NCT02795858 · Registry updated: 2025-02-19

Condition / research focus: Carcinoid Tumors
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2016-06-14. Completion: 2023-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ramucirumab (drug) — also listed as: Cyramza
Somatostatin Analog (drug) — also listed as: octreotide, lanreotide

Where the study takes place — 2 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

ClinicalTrials.gov · NCT02691078 · Registry updated: 2025-02-04

Condition / research focus: Neuroendocrine Tumors
Sponsor: Latin American Cooperative Oncology Group
Countries with listed sites: Brazil
Registry dates and results: Start: 2016-07. Completion: 2018-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide (other)

Where the study takes place — 1 listed sites

Instituto do Cérebro do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

ClinicalTrials.gov · NCT02736448 · Registry updated: 2025-01-13

Condition / research focus: Gastro-entero-pancreatic Neuroendocrine Tumors
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2016-05. Completion: 2023-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Capecitabine (drug)
Lu-PRRT (drug)
SS-LAR (drug)

Where the study takes place — 1 listed sites

Irst Irccs
Meldola, FC, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Polydeoxyribonucleotide for Elbow Lateral Epicondylitis

ClinicalTrials.gov · NCT06753630 · Registry updated: 2024-12-31

Condition / research focus: Lateral Epicondylitis; Extracorporeal Shockwave Therapy; Muscle Strengthening
Sponsor: Chuncheon Sacred Heart Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2014-11-20. Completion: 2016-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Extensor Muscle Strengthening Exercise (behavioral)
Extracorporeal Shockwave Therapy (procedure)
Saline injection (Octreotide LAR placebo) (drug)
Polydeoxyribonucleotide Injection (drug)

Where the study takes place — 1 listed sites

Chuncheon Sacred Heart Hospital
Chuncheon, Gangwon-do, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

ClinicalTrials.gov · NCT04917484 · Registry updated: 2024-12-09

Condition / research focus: Neuroendocrine Neoplasm
Sponsor: Tine Gregersen, MD
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-02-01. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lu-177-DOTA-Octreotide (drug)

Where the study takes place — 1 listed sites

Aarhus University Hospital, department of Nuclear medicine and PET centre
Aarhus, Palle Juul-Jensens Boulevard, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

ClinicalTrials.gov · NCT05833217 · Registry updated: 2024-12-04

Condition / research focus: Long COVID; Insulin Resistance; Insulin Sensitivity
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-06. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Adipose Tissue Biopsy (procedure)
Steady State Plasma Glucose (SSPG) Test (diagnostic_test) — also listed as: Insulin Sensitivity Test

Where the study takes place — 2 listed sites

Clinical and Translational Research Unit
Palo Alto, California, United States
Site recruitment: Enrolling by invitation
Stanford Health
Palo Alto, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

ClinicalTrials.gov · NCT04871204 · Registry updated: 2024-10-31

Condition / research focus: Esophageal Cancer; Gastric Cancer
Sponsor: Fredrik Klevebro
Countries with listed sites: Sweden
Registry dates and results: Start: 2021-06-16. Completion: 2024-02-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide Injection (drug)

Where the study takes place — 1 listed sites

Karolinska University Hospital, Huddinge
Stockholm, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

ClinicalTrials.gov · NCT06505395 · Registry updated: 2024-08-26

Condition / research focus: Gastrointestinal Neuroendocrine Pancreatic Tumor
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-30. Completion: 2028-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SYHX2008 injection (drug)
Sandostatin LAR@ (drug)

Where the study takes place — 1 listed sites

Chinese PLA General Hosptial
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

ClinicalTrials.gov · NCT06045260 · Registry updated: 2024-08-13

Condition / research focus: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2023-09-13. Completion: 2027-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

177Lu-DOTATOC (drug)

Where the study takes place — 2 listed sites

AUSL Romagna - Ospedale "M. Bufalini"
Cesena, Forlì-Cesena, Italy
Site recruitment: Not yet recruiting
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Meldola, Forlì-Cesena, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Sandostatin LAR® in Acromegaly

ClinicalTrials.gov · NCT01424241 · Registry updated: 2024-07-24

Condition / research focus: Acromegaly
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2006-10. Completion: 2014-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sandostatin LAR (drug)

Where the study takes place — 1 listed sites

Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

Dexamethasone/Pancreatic Clamp P&F

ClinicalTrials.gov · NCT06126354 · Registry updated: 2024-07-10

Condition / research focus: Insulin Resistance; Prediabetic State; Non-Alcoholic Fatty Liver Disease; Overweight and Obesity
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-01. Completion: 2026-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (12)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin human (drug) — also listed as: Novolin-R, Humulin-R
Octreotide Acetate (drug) — also listed as: Octreotide Acetate IV
Glucagon (drug) — also listed as: Glucagon IV
Human Growth Hormone (drug) — also listed as: Omnitrope
Dexamethasone Oral (drug) — also listed as: Dexamethasone
[6,6-2H2] D-glucose (other) — also listed as: D2-glucose, D2G
20% D-glucose (aq) (drug) — also listed as: D20W
BOOST Plus (dietary_supplement)
Harvard Apparatus PHD ULTRA CP syringe pump (device)
Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer (device)
Normal saline (other) — also listed as: NaCl IV
Human albumin (other) — also listed as: Human albumin IV

Where the study takes place — 1 listed sites

Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

ClinicalTrials.gov · NCT05701241 · Registry updated: 2024-06-14

Condition / research focus: Gastroenteropancreatic Neuroendocrine Tumor
Sponsor: University Hospital, Antwerp
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2023-06-28. Completion: 2034-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatostatin analog (drug) — also listed as: lanreotide, octreotide, sandostatin, somatuline

Where the study takes place — 19 listed sites

AZ Klina
Brasschaat, Antwerp, Belgium
Site recruitment: Recruiting
AZ Rivierenland
Rumst, Antwerp, Belgium
Site recruitment: Active, not recruiting
Ghent University Hospital
Ghent, East Flanders, Belgium
Site recruitment: Active, not recruiting
VITAZ
Sint-Niklaas, East-Flanders, Belgium
Site recruitment: Recruiting
University Hospital Leuven
Leuven, Flemish Brabant, Belgium
Site recruitment: Recruiting
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Site recruitment: Active, not recruiting
AZ Monica
Antwerp, Belgium
Site recruitment: Not yet recruiting
GZA
Antwerp, Belgium
Site recruitment: Active, not recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium
Site recruitment: Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Site recruitment: Recruiting
H.U.B.
Brussels, Belgium
Site recruitment: Active, not recruiting
Antwerp University Hospital
Edegem, Belgium
Site recruitment: Recruiting
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium
Site recruitment: Active, not recruiting
Rijnstate
Arnhem, Gelderland, Netherlands
Site recruitment: Recruiting
Maastricht UMC+
Maastricht, Limburg, Netherlands
Site recruitment: Recruiting
Maxima Medisch Centrum
Eindhoven, North Brabant, Netherlands
Site recruitment: Active, not recruiting
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Site recruitment: Active, not recruiting
UMC Groningen
Groningen, Netherlands
Site recruitment: Recruiting
Erasmus MC
Rotterdam, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

ClinicalTrials.gov · NCT05359146 · Registry updated: 2024-04-19

Condition / research focus: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Sponsor: University Hospital, Basel, Switzerland
Countries with listed sites: Switzerland
Registry dates and results: Start: 2023-03-28. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

161Tb-DOTA-LM3 (drug)
177Lu-DOTATOC (drug)

Where the study takes place — 1 listed sites

Division of Nuclear Medicine, University Hospital Basel
Basel, Switzerland
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

ClinicalTrials.gov · NCT01070758 · Registry updated: 2024-04-18

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide autogel (drug) — also listed as: Somatuline autogel

Where the study takes place — 1 listed sites

Pediatric Endocrinology Unit, Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Resection of the Esophagus and Subsequent Weight Loss

ClinicalTrials.gov · NCT03377660 · Registry updated: 2024-03-27

Condition / research focus: Esophageal Cancer; Weight Gain; Eating Behavior; Food Reward
Sponsor: Imperial College London
Countries with listed sites: Ireland
Registry dates and results: Start: 2018-01-01. Completion: 2023-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clinical treatment (other)

Where the study takes place — 1 listed sites

Conway Institute, UCD
Dublin, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

ClinicalTrials.gov · NCT06300216 · Registry updated: 2024-03-08

Condition / research focus: Neuroendocrine Tumors
Sponsor: Qilu Hospital of Shandong University
Countries with listed sites: China
Registry dates and results: Start: 2024-03-26. Completion: 2028-05-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide microspheres (drug)

Where the study takes place — 1 listed sites

Qilu hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →